Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Shares of VKTX stock opened at $24.99 on Friday. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.86. The company has a market capitalization of $2.81 billion, a P/E ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a ...

In a report released today, George Farmer from Scotiabank reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price ...

Viking Therapeutics VKTX is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement. Analysts estimate that Viking ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and ...